Partial response

8 (21.6%)

Stable disease

12 (32.4%)

Progressive disease

11 (29.7%)

Not evaluated

6 (16.2%)

Objective RR (95% CI)

21.6% (11.4 - 37.2)

Disease control rate (95% CI)

54.1% (35.9 - 66.6)

1-year survival

56.6% (38.4 - 71.2)

Median PFS (95% CI)

Non-selected EGFR mutated EGFR wild-type EGFR unknown

4.4 months (2.2 - 10.7)

12.6 months (2.2 - 19.9)

2.1 months (1.0 - 5.5)

3.9 months (1.0 - 11.0)

Median OS (95% CI)

Non-selected EGFR mutated EGFR wild-type EGFR unknown

14.9 months (9.2 - NR)

NR (5.3 - NR)

9.2 months (2.3 - 14.9)

10.5 months (1.1 - NR)